Claus Kremoser
Amministratore Delegato presso Phenex Pharmaceuticals AG
Posizioni attive di Claus Kremoser
Società | Posizione | Inizio | Fine |
---|---|---|---|
Phenex Pharmaceuticals AG
Phenex Pharmaceuticals AG Pharmaceuticals: GenericHealth Technology Phenex Pharmaceuticals AG engages in the research and development of small molecule drugs focusing on the identification and analysis of selective drug candidates that target nuclear receptors. It also offers its resources and capabilities in the field of nuclear receptors to customers in the pharmaceutical and other life science industries. The company was founded by Claus Kremoser in 2002 and is headquartered in Ludwigshafen, Germany. | Amministratore Delegato | 21/09/2002 | - |
Fondatore | 02/09/2009 | - | |
Presidente | 09/09/2009 | 19/05/2010 | |
WMT AG
WMT AG Miscellaneous Commercial ServicesCommercial Services WMT AG is a German research company that specializes in developing cancer therapies. WMT was founded in 2020 by Yves Guillermet and Claus Kremoser, with Claus Kremoser serving as the CEO since 2020. | Direttore/Membro del Consiglio | 01/01/2020 | - |
Amministratore Delegato | 01/01/2020 | - | |
Fondatore | 01/01/2020 | - |
Storia della carriera di Claus Kremoser
Precedenti posizioni note di Claus Kremoser
Società | Posizione | Inizio | Fine |
---|---|---|---|
Cardior Pharmaceuticals GmbH
Cardior Pharmaceuticals GmbH Pharmaceuticals: MajorHealth Technology Cardior Pharmaceuticals GmbH develops, manufactures and wholesales drugs. It focuses on the discovery, development and clinical validation of noncoding RNA therapeutics targeting microRNAs as medicines for patients with various forms of heart failure. The company was founded by Sandor Batkai, Claudia Ulbrich, and Thomas Thum on July 21, 2016 and is headquartered in Hannover, Germany. | Presidente | - | - |
Avelas Biosciences, Inc.
Avelas Biosciences, Inc. Medical/Nursing ServicesHealth Services Avelas Biosciences, Inc. develops integrated suite of therapeutic and imaging agents for treatment of cancer. It develops AVB-620, an intravenously administered in vivo fluorescent protease activatable peptide that detects, marks, and diagnoses cancer. The company was founded by Yon Chien Tsien, Quyen T. Nguyen and Michael A. Whitney in 2008 and is headquartered in La Jolla, CA. | Direttore/Membro del Consiglio | 01/05/2015 | - |
Statistiche
Distribuzione geografica
Germania | 4 |
Stati Uniti | 2 |
Posizioni
Chief Executive Officer | 2 |
Chairman | 2 |
Founder | 2 |
Settori
Health Technology | 3 |
Health Services | 2 |
Commercial Services | 2 |
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Società collegate
Aziende private | 4 |
---|---|
Phenex Pharmaceuticals AG
Phenex Pharmaceuticals AG Pharmaceuticals: GenericHealth Technology Phenex Pharmaceuticals AG engages in the research and development of small molecule drugs focusing on the identification and analysis of selective drug candidates that target nuclear receptors. It also offers its resources and capabilities in the field of nuclear receptors to customers in the pharmaceutical and other life science industries. The company was founded by Claus Kremoser in 2002 and is headquartered in Ludwigshafen, Germany. | Health Technology |
Avelas Biosciences, Inc.
Avelas Biosciences, Inc. Medical/Nursing ServicesHealth Services Avelas Biosciences, Inc. develops integrated suite of therapeutic and imaging agents for treatment of cancer. It develops AVB-620, an intravenously administered in vivo fluorescent protease activatable peptide that detects, marks, and diagnoses cancer. The company was founded by Yon Chien Tsien, Quyen T. Nguyen and Michael A. Whitney in 2008 and is headquartered in La Jolla, CA. | Health Services |
Cardior Pharmaceuticals GmbH
Cardior Pharmaceuticals GmbH Pharmaceuticals: MajorHealth Technology Cardior Pharmaceuticals GmbH develops, manufactures and wholesales drugs. It focuses on the discovery, development and clinical validation of noncoding RNA therapeutics targeting microRNAs as medicines for patients with various forms of heart failure. The company was founded by Sandor Batkai, Claudia Ulbrich, and Thomas Thum on July 21, 2016 and is headquartered in Hannover, Germany. | Health Technology |
WMT AG
WMT AG Miscellaneous Commercial ServicesCommercial Services WMT AG is a German research company that specializes in developing cancer therapies. WMT was founded in 2020 by Yves Guillermet and Claus Kremoser, with Claus Kremoser serving as the CEO since 2020. | Commercial Services |
- Borsa valori
- Insiders
- Claus Kremoser
- Esperienza